Genetics of Osteoarthritis and Joint Replacement Recovery: Key to Precision Rehabilitation
Genetics of Osteoarthritis and Joint Replacement Recovery: Key to Precision Rehabilitation
批准号:
10535425
负责人:
Jasvinder A Singh
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-08-01 至 2023-07-31
关键词:
AccountingActivities of Daily LivingAdmixtureAge-YearsArthritisDataDegenerative polyarthritisDiagnosisDiseaseDisease ProgressionEthnic groupFailureGeneral PopulationGeneticGoalsHabilitationHealth Care CostsHealthcare SystemsHeritabilityHeterogeneityHip region structureHospitalizationIncidenceIndividualKneeLife StyleMediatingMeta-AnalysisOperative Surgical ProceduresOutcomePainParticipantPhenotypePrevalencePublic HealthRecording of previous eventsRecoveryRehabilitation therapyReplacement ArthroplastyResourcesSurveysTestingTraumatic ArthropathyTreatment CostVariantVeteransbiobankcohortcommon symptomcomorbiditydisabilityend stage diseaseexperiencegenetic informationgenetic predictorsgenetic variantgenome wide association studyhealth care service utilizationhealth related quality of lifehip replacement arthroplastyimproved mobilityknee replacement arthroplastymulti-ethnicpatient orientedprimary outcomeprognosticprogramsrecruitrehabilitation strategyresponsesecondary analysissecondary outcomesuccesstargeted treatment
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The societal and patient-centered impacts of end-stage osteoarthritis (OA) among Veterans – including a
significant proportion suffering from post-traumatic arthritis – are profound: (i) VA healthcare costs for
treatment exceed $880 million annually; (ii) ~30% of Veterans in the VA healthcare system have OA, which is
a significantly higher rate than the general population; (iii) each year, 10,000 Veterans with end-stage arthritis
undergo total hip (n~3500) or knee (n~6500) arthroplasty (THA/TKA) and subsequent rehabilitation; (iv)
Veterans who undergo THA/TKA experience profound deficits in health-related quality of life (HRQL), severe
functional limitations in activities of daily living (ADL), increased healthcare utilization, and higher incidence of
comorbidities and hospitalization; and (v) incidence of moderate-severe functional limitations 2-5 years post-
surgery is 30-35% post-THA and 46-50% post-TKA despite prescribed rehabilitation. OA has a strong genetic
component with heritability estimates >30%. Pain is the most common symptom, contributing to disability and
decreased HRQL. Major phenotypic predictors of post-THA/TKA mobility limitation and pain have been
identifed. However, genetic predictors of both the progression of OA and success of THA/TKA recovery are as
yet unknown. Such discovery would fuel progress toward precision pre-habilitation and post-surgical
rehabilitation among Veterans. We seek to leverage the rich MVP resource to test the overarching
hypothesis that genetic variants explain a meaningful proportion of OA prevalence, progression to end-stage
disease leading to THA/TKA, and recovery success. This hypothesis will be tested with three specific aims.
Aim 1: To identify genetic variants associated with OA. We will perform GWAS in 292,516 MVP participants
40-80 years of age – of which 90,000 carry an OA diagnosis – in an effort to replicate known and identify new
genetic variants and regions associated with OA. As a secondary analysis, we will perform GWAS to identify
genetic variants associated with OA among 3,696 Veterans with post-traumatic arthritis. We will attempt to
replicate significant findings using data on 392,304 individuals in the UK Biobank, of which 41,217 have OA.
Aim 2: To identify genetic variants prognostic of progression to end-stage OA, as indicated by THA/TKA. We
will perform GWAS in the 90,000 MVP participants with OA to identify variants associated with reaching the
end-stage (i.e. THA/TKA). Within this cohort with diagnosed OA, we will identify genetic variants unique to the
subpopulation that progressed to end-stage – i.e. the 7,600 MVP participants who have undergone THA or
TKA subsequent to OA diagnosis. As a secondary analysis, we will perform GWAS to identify genetic variants
associated with revision surgery within 5 years of the initial THA/TKA, suggesting unique genetic variants that
may predispose some Veterans to poor adaptations to the initial THA/TKA. We will replicate significant findings
using data from 13,071 THA and 12,794 TKA in the UK Biobank. Exploratory Aim: To identify genetic variants
prognostic of THA/TKA recovery defined by mobility limitation (primary outcome), pain, and HRQL (secondary
outcomes). We will perform GWAS among the 7,600 MVP participants with past THA/TKA to identify variants
associated with recovery success or failure, as indicated by MVP Baseline and Lifestyle survey responses. As
a secondary analysis, we will investigate whether rehabilitation mediates the relationship between genetic
variants and THA/TKA recovery. We will maximize heterogeneity using two strategies: (i) By performing GWAS
in each major ethnic group independently and combining results using meta-analysis accounting for trans-
ethnic admixture; and (ii) By analyzing the entire MVP cohort to perform a multi-ethnic GWAS. The ultimate
goal is to identify genetic variants prognostic of OA as well as poor OA and THA/TKA outcomes to develop
targeted, precision pre-habilitation and post-surgical rehabilitation strategies improving mobility function,
HRQL, and healthcare utilization among Veterans.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Genetics of Osteoarthritis and Joint Replacement Recovery: Key to Precision Rehabilitation
-
批准号:10643606
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2023
-
负责人:Jasvinder A Singh
-
依托单位:
Genetics of Osteoarthritis and Joint Replacement Recovery: Key to Precision Rehabilitation
-
批准号:10174848
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2018
-
负责人:Jasvinder A Singh
-
依托单位:
Genetics of Osteoarthritis and Joint Replacement Recovery: Key to Precision Rehabilitation
-
批准号:10839541
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2018
-
负责人:Jasvinder A Singh
-
依托单位:
STorytelling to Improve DiseasE outcomes in GoUT: The STRIDE-GO Study
-
批准号:10178095
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2016
-
负责人:Jasvinder A Singh
-
依托单位:
STorytelling to Improve DiseasE outcomes in GoUT: The STRIDE-GO Study
-
批准号:9981438
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2016
-
负责人:Jasvinder A Singh
-
依托单位:
STorytelling to Improve DiseasE outcomes in GoUT: The STRIDE-GO Study
-
批准号:10179468
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2016
-
负责人:Jasvinder A Singh
-
依托单位:
STorytelling to Improve DiseasE outcomes in GoUT: The STRIDE-GO Study
-
批准号:9085817
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2016
-
负责人:Jasvinder A Singh
-
依托单位:
SToRytelling to Improve DiseasE outcomes in Gout: The STRIDE-GO Study
-
批准号:8783912
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2014
-
负责人:Jasvinder A Singh
-
依托单位:
Project 4: Protecting Renal functiOn with Urate-lowering Drugs (PROUD)
-
批准号:10017010
-
项目类别:
-
资助金额:$19.9万
-
财政年份:2012
-
负责人:Jasvinder A Singh
-
依托单位:
Project 4: Protecting Renal functiOn with Urate-lowering Drugs (PROUD)
-
批准号:10263207
-
项目类别:
-
资助金额:$23.28万
-
财政年份:2012
-
负责人:Jasvinder A Singh
-
依托单位:
Project 4: Protecting Renal functiOn with Urate-lowering Drugs (PROUD)
-
批准号:9767032
-
项目类别:
-
资助金额:$19.57万
-
财政年份:--
-
负责人:Jasvinder A Singh
-
依托单位:
Project 4: Protecting Renal functiOn with Urate-lowering Drugs (PROUD)
-
批准号:9370393
-
项目类别:
-
资助金额:$23.0万
-
财政年份:--
-
负责人:Jasvinder A Singh
-
依托单位:
海外基金